

Taipei Nangang Exhibition Center, Hall 2, Meeting room C



Patient-centric approaches to aflibercept treatment in nAMD/PCV

19 November 2022 | 12.15-13.15 (GMT+8)

Chair: Chang-Hao Yang

TIME	SESSION	SPEAKERS
12.15–12.20	Welcome and introductions	Chang-Hao Yang
12.20–13.00	A decade of aflibercept in nAMD and PCV: what have we learned?	John Kitchens, Gemmy Cheung
13.00–13.10	Innovating patient care with aflibercept: what does the future hold?	Michael Stewart
13.10–13.15	Summary and close	Chang-Hao Yang

APVRS, Asia-Pacific Vitreo-retina Society. nAMD, neovascular age-related macular degeneration. PCV, polypoidal choroidal vasculopathy.

This symposium is organised and funded by Bayer.

For prescribing and safety profile information for aflibercept 2 mg solution for injection, please consult local guidance.

Bayer (South East Asia) Pte Ltd.

2, Tanjong Katong Road #07-01, Paya Lebar Quarter 3, Singapore 437161.

Tel: +65 6496 1888 | Fax: +65 6496 1491



Taipei Nangang Exhibition Center, Hall 2, Meeting room C



Optimising DME management for meaningful outcomes with aflibercept

20 November 2022 | 12.15-13.15 (GMT+8)

Chair: Lee-Jen Chen

TIME	SESSION	SPEAKERS
12.15–12.20	Welcome and introductions	Lee-Jen Chen
12.20–13.00	From RCTs to the real world with aflibercept: what have we learned?	Michael Stewart, Gavin Tan
13.00–13.10	Innovating patient care with aflibercept: what does the future hold?	John Kitchens
13.10–13.15	Summary and close	Lee-Jen Chen

APVRS, Asia-Pacific Vitreo-retina Society. DME, diabetic macular oedema. RCT, randomised controlled trial.

This symposium is organised and funded by Bayer.

For prescribing and safety profile information for aflibercept 2 mg solution for injection, please consult local guidance.

Bayer (South East Asia) Pte Ltd.

2, Tanjong Katong Road #07-01, Paya Lebar Quarter 3, Singapore 437161.

Tel: +65 6496 1888 | Fax: +65 6496 1491